| Trial | Sponsor | Phase | Status | Primary completion |
|---|
| Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPCNCT01995058 | Exelixis | Phase 2 | Terminated | 2014-11Actual |
| Window of Opportunity Study of VS-6063 (Defactinib) in Surgical Resectable Malignant Pleural Mesothelioma ParticipantsNCT02004028 | VSTM | Phase 2 | Terminated | 2019-06-19Actual |
| Proof of Concept of VLY-686 in Subjects With Treatment-Resistant Pruritus Associated With Atopic DermatitisNCT02004041 | Vanda Pharmaceuticals | Phase 2 | Completed | 2015-02-19Actual |
| Phase 2 Study to Investigate the Efficacy and Safety of Aldoxorubicin in Subjects With GlioblastomaNCT02014844 | IBRX | Phase 2 | Completed | 2016-12Actual |
| Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study of Autologous MSC-NTF Cells in Patients With ALSNCT02017912 | Brainstorm-Cell Therapeutics | Phase 2 | Completed | 2016-03Actual |
| A Study to Investigate ALDOXORUBICIN in HIV-infected Subjects With Kaposi's SarcomaNCT02029430 | IBRX | Phase 2 | Completed | 2016-04-25Actual |
| Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart FailureNCT02032004 | Mesoblast, Inc. | Phase 3 | Completed | 2020-01-30Actual |
| Phase 3 Study to Treat Patients With Soft Tissue SarcomasNCT02049905 | IBRX | Phase 3 | Completed | 2017-05Actual |
| Open Label Study to Evaluate Efficacy and Long Term Safety of LUM001 (Maralixibat) in the Treatment of Cholestatic Liver Disease in Patients With Progressive Familial Intrahepatic CholestasisNCT02057718 | MIRM | Phase 2 | Completed | 2020-05-08Actual |
| A Multicenter Study to Determine the Depth and Duration of Hepatitis B Surface Antigen (HBsAg) Reduction After Single or Multiple Doses of ARC-520, in Combination With Entecavir in Patients With Chronic Hepatitis B Virus (HBV) InfectionNCT02065336 | Arrowhead Pharmaceuticals | Phase 2 | Terminated | 2017-01Actual |
| Long-term Follow-up Study of GLPG0634 in Active Rheumatoid Arthritis ParticipantsNCT02065700 | LKFT | Phase 2 | Completed | 2023-01-19Actual |
| Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)NCT02077192 | Rigel Pharmaceuticals | Phase 3 | Completed | 2020-06-02Actual |
| Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular Carcinoma (HCC)NCT02112656 | Imunon | Phase 3 | Completed | 2020-04-27Actual |
| Comparator Study of the Effect of Glycopyrrolate and Glycopyrronium in Subjects With Axillary HyperhidrosisNCT02129660 | Journey Medical Corporation | Phase 2 | Completed | 2015-01Actual |
| Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic PruritusNCT02143648 | Trevi Therapeutics | Phase 2, Phase 3 | Completed | 2015-07Actual |
| Open Label Extension Study of Nalbuphine HCl ER in Hemodialysis Patients With Uremic PruritusNCT02143973 | Trevi Therapeutics | Phase 2, Phase 3 | Completed | 2016-01Actual |
| A Study to Evaluate the Efficacy and Safety of NexoBrid in Subjects With Thermal BurnsNCT02148705 | MDWD | Phase 3 | Completed | 2018-06-12Actual |
| Study of Nalbuphine HCl ER Tablets in Patients With Prurigo NodularisNCT02174419 | Trevi Therapeutics | Phase 2, Phase 3 | Completed | 2016-08Actual |
| Open Label Extension Study of Nalbuphine HCl ER in Patients With Prurigo NodularisNCT02174432 | Trevi Therapeutics | Phase 2, Phase 3 | Completed | 2017-09-03Actual |
| Extension Study Assessing Long Term Safety and Efficacy of IONIS-TTR Rx in Familial Amyloid Polyneuropathy (FAP)NCT02175004 | IONS | Phase 3 | Completed | 2020-09-11Actual |
| Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung CancerNCT02200757 | IBRX | Phase 2 | Completed | 2017-05-15Actual |
| Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) Extension Study for Subjects Previously Enrolled in Triheptanoin StudiesNCT02214160 | RARE | Phase 2 | Completed | 2020-12-03Actual |
| Safety and Efficacy Study of OMS721 in Patients With Thrombotic MicroangiopathiesNCT02222545 | Omeros Corporation | Phase 2 | Completed | 2020-01-30Actual |
| Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)NCT02227251 | KPTI | Phase 2 | Terminated | 2026-06-02Actual |
| A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar CarcinomaNCT02234986 | CASI pharmaceuticals, Inc. | Phase 2 | Completed | 2018-06-30Actual |
| Oral Ibrexafungerp (SCY-078) vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive CandidiasisNCT02244606 | SCYX | Phase 2 | Completed | 2016-06Actual |
| Efficacy and Safety of Intramuscular PDA-002 in Subjects With Diabetic Foot Ulcer With and Without PAD.NCT02264288 | Celularity Incorporated | Phase 2 | Terminated | 2018-02-27Actual |
| Safety and Efficacy Study of TNX-102 SL in Subjects With Military-Related PTSD and Related ConditionsNCT02277704 | Tonix Pharmaceuticals, Inc. | Phase 2 | Completed | 2016-05Actual |
| A Study to Evaluate the Efficacy and Safety of NexoBrid in Children With Thermal Burns Compared the Standard of CareNCT02278718 | MDWD | Phase 3 | Completed | 2021-04Actual |
| Evaluate SAGE-547 in Female Participants With Severe Postpartum DepressionNCT02285504 | SUPN | Phase 2 | Completed | 2015-06-05Actual |
Trial details
- Registry ID
- NCT01995058
- Phase
- Phase 2
Trial details
- Registry ID
- NCT02004028
- Phase
- Phase 2
Trial details
- Registry ID
- NCT02004041
- Phase
- Phase 2
Trial details
- Registry ID
- NCT02014844
- Phase
- Phase 2
Trial details
- Registry ID
- NCT02017912
- Phase
- Phase 2
Trial details
- Registry ID
- NCT02029430
- Phase
- Phase 2
Trial details
- Registry ID
- NCT02032004
- Phase
- Phase 3
Trial details
- Registry ID
- NCT02049905
- Phase
- Phase 3
Trial details
- Registry ID
- NCT02057718
- Phase
- Phase 2
Trial details
- Registry ID
- NCT02065336
- Phase
- Phase 2
Trial details
- Registry ID
- NCT02065700
- Phase
- Phase 2
Trial details
- Registry ID
- NCT02077192
- Phase
- Phase 3
Trial details
- Registry ID
- NCT02112656
- Phase
- Phase 3
Trial details
- Registry ID
- NCT02129660
- Phase
- Phase 2
Trial details
- Registry ID
- NCT02143648
- Phase
- Phase 2, Phase 3
Trial details
- Registry ID
- NCT02143973
- Phase
- Phase 2, Phase 3
Trial details
- Registry ID
- NCT02148705
- Phase
- Phase 3
Trial details
- Registry ID
- NCT02174419
- Phase
- Phase 2, Phase 3
Trial details
- Registry ID
- NCT02174432
- Phase
- Phase 2, Phase 3
Trial details
- Registry ID
- NCT02175004
- Phase
- Phase 3
Trial details
- Registry ID
- NCT02200757
- Phase
- Phase 2
Trial details
- Registry ID
- NCT02214160
- Phase
- Phase 2
Trial details
- Registry ID
- NCT02222545
- Phase
- Phase 2
Trial details
- Registry ID
- NCT02227251
- Phase
- Phase 2
Trial details
- Registry ID
- NCT02234986
- Phase
- Phase 2
Trial details
- Registry ID
- NCT02244606
- Phase
- Phase 2
Trial details
- Registry ID
- NCT02264288
- Phase
- Phase 2
Trial details
- Registry ID
- NCT02277704
- Phase
- Phase 2
Trial details
- Registry ID
- NCT02278718
- Phase
- Phase 3
Trial details
- Registry ID
- NCT02285504
- Phase
- Phase 2
Primary completion marks the end of data collection for the main study measures, not a results publication date.